Phio Pharmaceuticals Corp. – NASDAQ:PHIO

Add to watchlist

$2.05

+0.11

+6.22%

Market closed

Open in about 8 hours

-61.78%

month

-61.78%

quarter

+156.99%

year

Market Cap	2.56M
Enterprise value	N/A

P/E	-0.55
EV/Sales	N/A
EV/EBITDA	0.32
Price/Sales	N/A
Price/Book	0.57
PEG ratio	-0.02
EPS	-3.59

Revenue	N/A
EBITDA	-9.18M
Income	-9.37M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Profit margin
Jun 2023	0	-2.54M
Sep 2023	0	-2.78M
Dec 2023	30K	-1.89M	-6316.67%
Mar 2024	0	-2.15M

Phio Pharmaceuticals Corp. Financials Estimate

Q Y

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Analyst Estimates
2025	75M	7.87M	10.5%

Analysts Price target
Financials & Ratios estimates

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Debt to assets
Jun 2023	12296000	2.39M	19.45%
Sep 2023	9539000	2.32M	24.38%
Dec 2023	9364000	1.63M	17.45%
Mar 2024	6853000	1.24M	18.23%

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Cash Flow
Jun 2023	-2.77M	-5K	5.04M
Sep 2023	-2.9M	0	0
Dec 2023	-2.37M	0	2.40M
Mar 2024	-2.01M	0	-4K

Phio Pharmaceuticals Corp. alternative data

Phio Pharmaceuticals Corp.
Employees

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Employee count
Aug 2023	9
Sep 2023	9
Oct 2023	9
Nov 2023	9
Dec 2023	9
Jan 2024	9
Feb 2024	9
Mar 2024	9
Apr 2024	9
May 2024	8
Jun 2024	8
Jul 2024	8

Phio Pharmaceuticals Corp.
Hedge Funds Holdings Q1 2023

30.33% +26.12%

of PHIO is owned by hedge funds

5 -6

hedge funds hold PHIO stock

28.72K -19.20K

shares is hold by hedge funds

PHIO hedge funds holdings changes

Phio Pharmaceuticals Corp.
Insider Trading

Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	2500	0
Jun 2024	2000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	7 Jun 2024	BITTERMAN ROBERT J director, officer: President & CEO director, officer: President & ..	Common stock, $0.0001 par value	1,000	$0.74	$740
Purchase	6 Jun 2024	BITTERMAN ROBERT J director, officer: President & CEO director, officer: President & ..	Common stock, $0.0001 par value	1,000	$0.75	$750
Purchase	26 Feb 2024	BITTERMAN ROBERT J director, officer: President & CEO director, officer: President & ..	Common stock, $0.0001 par value	2,500	$0.91	$2,275
Purchase	1 Jul 2023	BITTERMAN ROBERT J director, officer: President & CEO director, officer: President & ..	Common stock, $0.0001 par value	1,000	$2.84	$2,840
Purchase	30 Jun 2023	BITTERMAN ROBERT J director, officer: President & CEO director, officer: President & ..	Common stock, $0.0001 par value	1,000	$2.88	$2,880
Purchase	14 Jun 2023	FERRARA ROBERT L director director	Common stock, $0.0001 par value	2,000	$3.1	$6,200
Purchase	14 Dec 2022	BITTERMAN ROBERT J director, officer: Interim Executive Ch.. director, officer: Interim Exec..	Common stock, $0.0001 par value	2,000	$0.39	$780
Purchase	7 Dec 2022	BITTERMAN ROBERT J director, officer: Interim Executive Ch.. director, officer: Interim Exec..	Common stock, $0.0001 par value	2,000	$0.39	$780
Purchase	5 Dec 2022	BITTERMAN ROBERT J director, officer: Interim Executive Ch.. director, officer: Interim Exec..	Common stock, $0.0001 par value	2,000	$0.43	$860
Purchase	2 Dec 2022	FERRARA ROBERT L director director	Common stock, $0.0001 par value	5,000	$0.41	$2,040

PHIO insider trading transactions

Phio Pharmaceuticals Corp.
Patents

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Inhibition of MAP4K4 through RNAi Filling date: 2 Jun 2015 Issue date: 22 Feb 2022	2 Jun 2015	22 Feb 2022
Application	Application METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 Filling date: 15 Jan 2021 Issue date: 11 Nov 2021	15 Jan 2021	11 Nov 2021
Application	Application IMMUNOTHERAPY OF CANCER Filling date: 15 Jan 2021 Issue date: 11 Nov 2021	15 Jan 2021	11 Nov 2021
Grant	Grant Utility: Reduced size self-delivering RNAI compounds Filling date: 7 Feb 2019 Issue date: 14 Sep 2021	7 Feb 2019	14 Sep 2021
Application	Application RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS Filling date: 15 Jan 2021 Issue date: 26 Aug 2021	15 Jan 2021	26 Aug 2021
Grant	Grant Utility: Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA Filling date: 19 Oct 2016 Issue date: 1 Jun 2021	19 Oct 2016	1 Jun 2021
Application	Application REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS Filling date: 21 Jul 2020 Issue date: 20 May 2021	21 Jul 2020	20 May 2021
Grant	Grant Utility: Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) Filling date: 6 Jul 2016 Issue date: 11 May 2021	6 Jul 2016	11 May 2021
Application	Application RNA INTERFERENCE IN OCULAR INDICATIONS Filling date: 12 May 2020 Issue date: 4 Mar 2021	12 May 2020	4 Mar 2021
Grant	Grant Utility: Immunotherapy of cancer Filling date: 2 Dec 2014 Issue date: 2 Mar 2021	2 Dec 2014	2 Mar 2021

PHIO patents

Phio Pharmaceuticals Corp.
Earnings Call Transcripts

Quarter	Transcript
Q3 2018 15 Nov 2018	Q3 2018 Earnings Call Transcript
Q2 2018 15 Aug 2018	Q2 2018 Earnings Call Transcript
Q1 2018 13 May 2018	Q1 2018 Earnings Call Transcript
Q4 2017 26 Mar 2018	Q4 2017 Earnings Call Transcript

PHIO earnings call transcripts

Phio Pharmaceuticals Corp.
Executives

Insider	Age	Since	Compensation
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. (1975) Pres, Chief Executive Officer & Director	50		$583,140

Phio Pharmaceuticals Corp.
Latest News

Thursday, 19 December 2024
14:28	Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	newsfilecorp.com
07:45	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762	newsfilecorp.com
Thursday, 12 December 2024
09:21	Phio Pharmaceuticals Announces Publication in Frontiers in Immunology	newsfilecorp.com
Tuesday, 10 December 2024
07:45	Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award	newsfilecorp.com
Tuesday, 3 December 2024
07:45	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
Tuesday, 19 November 2024
07:45	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study	newsfilecorp.com
Thursday, 14 November 2024
17:47	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update	newsfilecorp.com
Thursday, 7 November 2024
10:00	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	newsfilecorp.com
Friday, 1 November 2024
07:45	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
Friday, 18 October 2024
13:30	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
08:00	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series	newsfilecorp.com
Wednesday, 16 October 2024
08:00	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference	newsfilecorp.com
Monday, 7 October 2024
08:00	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells	newsfilecorp.com
Wednesday, 2 October 2024
08:00	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
Wednesday, 25 September 2024
08:00	INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society	newsfilecorp.com
Tuesday, 17 September 2024
08:00	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
Monday, 16 September 2024
08:00	Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA	newsfilecorp.com
Monday, 9 September 2024
07:00	Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference	newsfilecorp.com
Thursday, 29 August 2024
08:30	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series	newsfilecorp.com
Wednesday, 14 August 2024
17:00	Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update	newsfilecorp.com
Tuesday, 6 August 2024
08:00	Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound	newsfilecorp.com
Thursday, 1 August 2024
08:00	Phio Pharmaceuticals Announces New Chief Financial Officer	newsfilecorp.com
Friday, 12 July 2024
08:00	Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds	newsfilecorp.com
Monday, 8 July 2024
08:00	Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762	newsfilecorp.com
Friday, 5 July 2024
08:00	Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds	newsfilecorp.com
Tuesday, 2 July 2024
11:45	Phio Pharmaceuticals Announces Reverse Stock Split	newsfilecorp.com
Tuesday, 18 June 2024
07:30	Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging	newsfilecorp.com
Tuesday, 28 May 2024
07:30	Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762	newsfilecorp.com
Thursday, 23 May 2024
17:00	Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)	newsfilecorp.com
Friday, 17 May 2024
09:00	Phio Pharmaceuticals Secures New Investor	globenewswire.com

Frequently Asked Questions (FAQ)

What's the price of Phio Pharmaceuticals Corp. stock today?

One share of Phio Pharmaceuticals Corp. stock can currently be purchased for approximately $2.05.
When is Phio Pharmaceuticals Corp.'s next earnings date?

Unfortunately, Phio Pharmaceuticals Corp.'s (PHIO) next earnings date is currently unknown.
Does Phio Pharmaceuticals Corp. pay dividends?

No, Phio Pharmaceuticals Corp. does not pay dividends.
How much money does Phio Pharmaceuticals Corp. make?

Phio Pharmaceuticals Corp. has a market capitalization of 2.56M.
What is Phio Pharmaceuticals Corp.'s stock symbol?

Phio Pharmaceuticals Corp. is traded on the NASDAQ under the ticker symbol "PHIO".
What is Phio Pharmaceuticals Corp.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Phio Pharmaceuticals Corp.?

Shares of Phio Pharmaceuticals Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Phio Pharmaceuticals Corp.'s key executives?
Phio Pharmaceuticals Corp.'s management team includes the following people:
- Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. Pres, Chief Executive Officer & Director(age: 50, pay: $583,140)
How many employees does Phio Pharmaceuticals Corp. have?

As Jul 2024, Phio Pharmaceuticals Corp. employs 8 workers, which is 11% less then previous quarter.
When Phio Pharmaceuticals Corp. went public?

Phio Pharmaceuticals Corp. is publicly traded company for more then 13 years since IPO on 10 May 2012.
What is Phio Pharmaceuticals Corp.'s official website?

The official website for Phio Pharmaceuticals Corp. is phiopharma.com.
Where are Phio Pharmaceuticals Corp.'s headquarters?

Phio Pharmaceuticals Corp. is headquartered at 257 Simarano Drive, Marlborough, MA.
How can i contact Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp.'s mailing address is 257 Simarano Drive, Marlborough, MA and company can be reached via phone at +508 7673861.

Phio Pharmaceuticals Corp.

phiopharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

+508 7673861

257 Simarano Drive
Marlborough, MA 01752

CIK: 0001533040
ISIN: US71880W4024
CUSIP: 71880W303